ArticleInternational journal of genomics2026
Multilevel Genetic and Functional Assessment of an ARR3 Frameshift Variant in Early-Onset High Myopia.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset high myopia (eoHM) is a highly heritable ocular disorder, with pathogenic variants in the X-linked ARR3 gene (which encodes cone arrestin) being associated with a female-limited form of eoHM. However, the clinical manifestations of early truncating variants in ARR3 and their potential impact on the classic sex-limited pattern remain insufficiently understood. Methods: This study examined individuals with eoHM from a multigenerational Chinese family, utilizing whole-exome sequencing, Sanger validation, and segregation analysis to identify candidate variants. In silico predictions and protein structure modeling were conducted to assess the variant's pathogenicity. Furthermore, in cultured cells, quantitative real-time PCR, Western blotting, and fluorescence microscopy were used to evaluate ARR3 transcript expression and ARR3-related immunodetected signal after transfection with wild-type or mutant ARR3 constructs, thereby providing a preliminary functional assessment of the variant. Results: We discovered a novel frameshift variant, c.721delT (p.Y241Ifs∗3), which cosegregated with eoHM in the family and was absent in public population databases. Affected individuals, including hemizygous males, exhibited early-onset, high-degree myopia and fundus changes consistent with pathologic myopia. Functional assays in ARPE-19 cells showed that the mutant construct was associated with markedly reduced ARR3 mRNA expression and decreased ARR3 immunoreactivity compared with the wild-type construct. Because no direct cellular injury assay was performed, these in vitro findings were interpreted as preliminary expression-level evidence supporting a likely loss-of-function mechanism. Conclusion: The novel ARR3 frameshift variant c.721delT (p.Y241Ifs∗3) is likely pathogenic for eoHM and may alter the previously understood female-limited inheritance pattern. These findings expand the known mutation spectrum of ARR3 and enhance understanding of the role of cone arrestin dysfunction in the development of eoHM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.